|
 |
TysabriThis page contains recent news articles, when available, and an overview of Tysabri but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Overview: Tysabri (when available) In multiple sclerosis, lesions are believed to occur when activated inflammatory cells, including T-lymphocytes, cross the blood-brain barrier (BBB). Leukocyte migration across the BBB involves interaction between adhesion molecules on inflammatory cells, and their counter-receptors present on endothelial cells of the vessel wall. The clinical effect of natalizumab in multiple sclerosis may be a secondary result of its blockade of the molecular interaction of a 4b 1-integrin expressed by inflammatory cells with VCAM-1 on vascular endothelial cells, and with CS-1 and/or osteopontin expressed by parenchymal cells in the brain. For treatment of multiple sclerosis Mechanism Of Action: binds to the α4-subunit of 4 1 and 4 7 integrins expressed on the surface of all leukocytes except neutrophils, and inhibits the 4-mediated adhesion of leukocytes to their counter-receptor(s). News Articles on Natalizumab Biogen looks for a new leader - 06 Jan 2010 The company manufactures two MS treatments, Avonex and Tysabri, at its 175-acre RTP campus; it also handles patient support services. ... News & Observer Investors cheer departure of Biogen CEO Jim Mullen - 06 Jan 2010 The changes at Biogen come as the company struggles to overcome concerns about the safety of its most important product, the multiple sclerosis drug Tysabri ... Reuters William Young to succeed Ross as Biogen chairman - Dec 10, 2009 Cambridge, Massachusetts-based Biogen, which sells the multiple sclerosis drugs Avonex and Tysabri, also announced that former Thermo Fisher Scientific(TMO. ... Reuters Forget the Higher Doses - Dec 15, 2009 Whether it flops or not won't matter that much to Elan though; its near-term future will be determined by bapineuzumab and Tysabri. ... Motley Fool Black Box Drugs - Dec 23, 2009 The issue of a “black box warning? came up with Tysabri®, an intravenous medication used for treatment of some forms of MS. The drug was pulled off the ... WSOCtv.com Medical career, life affected by MS - Jan 4, 2010 Karen receives a monthly infusion of one of these, Tysabri, which has helped stabilize her, but it did not undo the damage already done, Joel Hall said. ... Frederick News Post (subscription) The 5 Worst Drug Companies of 2009 - Dec 24, 2009 Elan holds two potentially amazing drugs, Tysabri for MS and bapineuzumab, an in-development Alzheimer's drug. Despite these blessings, management shoots ... BNET 2010 Will Be A Defining Year For BIIB - Dec 22, 2009 If Biogen Idec can identify clinically relevant screening assays to predict the risk of PML related to Tysabri, it will be able to reestablish its bottom ... Benzinga Acorda's Fampridine: The First FDA Approval to Help MS Patient's Walk - Dec 14, 2009 Unlike the disease modifying drugs (Copaxone, Tysabri and the interferons) Fampridine SR was effective irrespective of MS subtype (relapsing remitting, ... Gerson Lehrman Group Vigabatrin (Sabril®): A New Epilepsy Drug -- With Strings Attached - Dec 31, 2009 The SHARE program is similar to the TOUCH (Tysabri Outreach Unified Commitment to Health) prescribing program for natalizumab (Tysabri®), which requires ... Medscape Multiple Sclerosis: A Breakthrough Is on the Way - Dec 30, 2009 Consider Tysabri, one of the most potent weapons against MS, which works by confining wayward immune cells in the bloodstream. The drug, made by Biogen Idec ... BusinessWeek Scottish Answer 15 Dec 09 - Dec 16, 2009 Ross Finnie (West of Scotland) (LD): To ask the Scottish Executive how many prescriptions for natalizumab, brand name Tysabri, have been dispensed in each ... DeHavilland (press release) (subscription) Oncology R&D Challenges & Opportunities - Dec 29, 2009 ...where she was responsible for the clinical development of AVONEX (Interferon beta-1a), Tysabri (natalizumab), and the company's oncology programs. ... Life Science Leader Magazine Study could hold key to MS treatment - Dec 20, 2009 Now, after disappointing results with medications, she has gone three years on the drug Tysabri without an exacerbation and can play the violin again. ... Buffalo News And the M&A/Alliance Deal of the Year Nominees Are ... - Dec 23, 2009 In return for roughly $1 billion in capital (slightly less after Elan got into a tussle with BiogenIdec about a potential change of control to Tysabri), ... The IN VIVO Blog (blog) Sergantieji IS negauna pažangių vaistų – našta valstybei didėja - Dec 14, 2009 Natalizumabo (Tysabri) reikėtų maždaug dešim?iai mūsų šalies ligonių. Gydymas šiuo vaistu nėra daug brangesnis, maždaug 30 proc. ... medicine.lt Cannabinoidi, serve una bussola per la legalità - Dec 10, 2009 ...perché continuare a spendere 3.000 euro al mese per la mia flebo di Tysabri, quando con 140 euro di Bedrocan si potevano ottenere risultati migliori??. ... Associazione Luca Coscioni Biogen Rethinking Disclosure Policies On MS Drug Tysabri - Nov 11, 2009 Tysabri's controversial history also has provoked fear in investors. Biogen withdrew the drug from the market for 18 months beginning in 2005 after three ... Wall Street Journal Biogen 3Q Net Jumps 34%; May Amend Tysabri Label - Oct 20, 2009 In addition, the Cambridge, Mass., company disclosed it is in talks to amend the label of MS drug Tysabri, its key growth driver sold with Elan Plc (ELN), ... Wall Street Journal Biogen Updates Tysabri Label To Reflect Risk With Longer Use - Nov 6, 2009 NEW YORK (Dow Jones)--Biogen Idec Inc. (BIIB) amended the US label of multiple sclerosis treatment Tysabri, sold with ... Wall Street Journal Biogen Idec falls as Elan plunges on potential Tysabri woes - Oct 23, 2009 According to the European Medicines Agency, regulators plan to meet to review Tysabri's safety record to see if any more precautions need to be taken. ... MarketWatch Elan Swings to a Profit as Tysabri Sales Rise - Oct 21, 2009 30 rose 6.5% to $283.7 million from $266.4 million, helped by increased sales of key drug Tysabri, as well as contract manufacturing revenue. ... Wall Street Journal Europe Regulators Report 4 PML Deaths On Tysabri Since '06 - Oct 29, 2009 One other death had been reported in a Tysabri patient since it was removed from the market for 18 months beginning in 2005 because of a link to progressive ... Wall Street Journal Biogen Idec's Social Media Ties Save Tysabri Again; FDA Watching - Nov 12, 2009 On November 2, Biogen Idec updated the prescribing label for its blockbuster multiple sclerosis drug Tysabri (natalizumab) ... BNET New drug therapies and promising research offer hope to MS sufferers - Nov 13, 2009 ..."All five" — Avonex, Betaseron, Copaxone, Rebif and Tysabri — "are drug therapies that attenuate the disease by helping control the intensity and frequency ... Canada.com Tysabri label gets updated PML risk info - Nov 9, 2009 As expected, Biogen Idec and Elan have amended the label of their multiple sclerosis med Tysabri. Some 23 cases of the scary brain infection progressive ... FiercePharma MS patient refuses to let life pass her by - Nov 13, 2009 Ms. Leslie has been on Tysabri, the newest drug for the treatment of MS, for the last two years. The drug is not a cure, but it can slow the progression of ... Canada.com Tysabri cuts hospitalisation rate - Oct 28, 2009 Irish pharmaceutical company Elan and its US partner Biogen said a new analysis of three late-stage clinical trials showed that their Tysabri medicine ... Irish Times Cost-Cutting Helps Pfizer Overcome Lower Sales - Oct 20, 2009 Another drug maker, Biogen Idec, said its profit rose 34 percent in the third quarter, helped by increased sales of its multiple sclerosis drug Tysabri. ... New York Times REG-Elan Corporation PLC Elan to Highlight Tysabri Data in Crohn's Disease at ... - Oct 20, 2009 The posters and presentations during ACG will highlight TYSABRI® (natalizumab) data in treating Crohn`s Disease. During a plenary session on inflammatory ... Reuters More Tysabri Problems; Time for a Biogen-Idec Credibility Check - Oct 30, 2009 Yes, there are 24 confirmed cases of PML (since Tysabri re-marketing in 2006). The FDA is still receiving and reviewing follow-up information on cases of ... BNET Biogen's a Buy - Nov 3, 2009 We view current valuation largely priced in for Tysabri concerns, posing limited downside; we are upgrading to buy. While we acknowledge that Biogen lacks ... Barron's 4-Star Stocks Poised to Pop: Elan - Oct 26, 2009 Tysabri has proven to have a high level of efficacy in the treatment of [multiple sclerosis]. ... Combined with some exciting Alzheimer's treatments coming ... msnbc.com EMEA: Another Tysabri Patient Develops PML, Brings Total to 24 - Nov 4, 2009 A new progressive multifocal leukoencephalopathy (PML) infection has been confirmed in a patient taking Tysabri, Biogen Idec and Elan's multiple sclerosis ... FDA news (subscription) REG-Elan Corporation PLC Subset Data from Two Randomized Phase 3 Trials Show ... - Oct 28, 2009 ..."Therefore, we were encouraged to see that TYSABRI reduced hospitalization rates, particularly in the more difficult-to-treat subsets of patients previously ... Reuters European Stocks Fall, Erasing Weekly Gain; Mobistar, Elan Drop - Oct 23, 2009 Elan Corp. sank 20 percent after its multiple sclerosis drug Tysabri was linked to 23 cases of a potentially fatal brain disease. ... Bloomberg Brain Disease Found in 3rd Patient on Roche's Rituxan - Oct 23, 2009 The brain disease has been linked to the multiple sclerosis drug Tysabri marketed by Cambridge, Massachusetts-based Biogen and Irish drugmaker Elan Corp. ... Bloomberg The Ticker - Nov 6, 2009 ...s Tysabri says a brain infection linked to the multiple sclerosis drug is more likely to occur the longer patients use it. ... Boston Herald FDA Grapples With Regulating Social Media Ads - Nov 11, 2009 When the FDA warned Biogen Idec Inc. (BIIB) earlier this year for search ads for Tysabri, a multiple sclerosis drug, the agency said linking to a page had ... Wall Street Journal Elan gets subpoena over MS drug, Tysabri - Nov 3, 2009 Tysabri is a prescription drug used to treat multiple sclerosis and has been available in Ireland since 2006. MS Ireland describes the drug as having ... Linex Legal (registration) Developers blueprint big biotech developments; Pfizer's job cuts since 2005 ... - Nov 9, 2009 Report > As expected, Biogen Idec and Elan have amended the label of their multiple sclerosis med Tysabri. Some 23 cases of the scary brain infection ... FierceBiotech REG-Elan Corporation PLC Elan Reports Third Quarter 2009 Financial Results - Oct 21, 2009 He added, "We are now afforded the opportunity to focus on growing Tysabri and EDT businesses, advancing our bioneurology pipeline and investing in unique ... Reuters Biogen Idec Reports Third Quarter 2009 Results - Oct 20, 2009 The increase was driven primarily by the continued growth of TYSABRI® (natalizumab) revenues, which were up 21% over the prior year to $207 million for the ... Reuters Midday Movers: Pump Up the Volume - Oct 23, 2009 Elan (ELN Quote) tumbled by $1, or 15.5%, to $5.44 after reports that European regulators are investigating reports of 23 cases of Tysabri patients with a ... TheStreet.com PDL BioPharma Q3 Profit Declines - Update - Oct 28, 2009 The company has revised its revenue view to include MedImmune royalties and its expectation of lower product sales growth in Avastin, Herceptin and Tysabri. ... RTT News The Ticker - Oct 20, 2009 Biogen Idec Inc. said profit rose 35 percent on higher sales of Tysabri. But the Cambridge firm's shares fell after it told investors that regulators may ... Boston Herald Julie's Low Dose Naltrexone Journal: Month 6 - Nov 2, 2009 My wife came off 20 months of Tysabri in May and has been on LDN exclusively ever since with no flares, a return of sensation almost everywhere in her body, ... About - News & Issues (blog) Eden posts jobs; Xenomics sues Sequenom on patent rights; - Oct 30, 2009 Article > European regulators offer yet another update on Tysabri-linked cases of progressive multifocal leukoencephalopathy: The grand total is now 24, ... FierceBiotech Elan Corporation, plc - SWOT Analysis - Oct 23, 2009 Elan's flagship product, Tysabri, is being marketed in collaboration with Biogen Idec for the treatment of multiple sclerosis and Crohn's disease. ... PRMinds (press release) US stock market opening report (November 12, 2009, Thursday) - Nov 12, 2009 ...(BBG) Biogen Idec – Co. is rethinking disclosure policies on MS drug tysabri, the co is re-evaluating the way it communicates new cases of a rare brain ... Stock Markets Review Subdued week ends with Iseq closing 1.6% down on day - Oct 23, 2009 ...group Elan plunged after it disclosed 10 new cases of PML, a deadly viral brain disorder linked to use of its multiple sclerosis (MS) drug Tysabri. ... Irish Times Other News To Note - Nov 10, 2009 Tysabri was withdrawn from the market in 2005 after being linked with PML and reintroduced in 2006 with stricter safety warnings. â? ... Therapeutics Daily (press release) (registration) European markets post weekly drop on growth concern - Oct 24, 2009 Elan Corp sank 22 percent as its multiple sclerosis drug Tysabri was linked to 23 cases of a potentially fatal brain disease. Valeo SA advanced 4.9 percent ... Taipei Times US HOT STOCKS: Apple, Boston Scientific, Bank of NY Mellon - Oct 20, 2009 ...as earnings topped expectations amid cost-cutting and strong sales of the biotechnology company's Tysabri multiple-sclerosis drug. ... Wall Street Journal Beleaguered banks take big hit - Oct 28, 2009 It closed with a gain of 3.11pc, despite some analysts questioning the 'blockbuster' status of its star drug Tysabri in the wake of more cases of the PML ... Irish Independent Research offers new hope to MS sufferers - Nov 10, 2009 ..."All five"--Avonex, Betaseron, Copaxone, Rebif and Tysabri-- "are drug therapies that attenuate the disease by helping control the intensity and frequency ... Calgary Herald Elan to highlight Tysabri data in Crohns Disease - Oct 20, 2009 Elan is to highlight Tysabri data in Crohn?s Disease at the American College of Gastroenterology annual scientific meeting. Elan Corporation and Biogen Idec ... IBTimes Biotech Takes It on the Chin in October - Nov 2, 2009 Biogen Idec's shares were hit following reports that the number of cases of a rare brain infection in patients taking Biogen's drug Tysabri is higher than ... Reuters UK Stocks Advance as GDP Report Suggests Rates to Remain Low - Oct 23, 2009 ...(ELN ID) dropped 88 euro cents, or 20 percent, to 3.42 euros in Dublin after its multiple sclerosis drug Tysabri was linked to 23 cases of a potentially ... Bloomberg Oils, pharmas drag down European shares at close - Oct 23, 2009 I) slumped 20 percent after European regulators said they have begun a review of the multiple sclerosis drug Tysabri following reports of 23 cases of a ... Reuters Nice Quarter, Teva. What Will You Buy Next? - Nov 3, 2009 ...and they may be able to maintain that growth as Biogen Idec (Nasdaq: BIIB) and Elan (NYSE: ELN) continue to struggle with Tysabri's side-effect issues. ... Motley Fool ADR REPORT: ADRs Close Down, With Every Sector Negative - Oct 20, 2009 Biogen Idec Inc. (BIIB) disclosed it is in talks to amend the label of MS drug Tysabri, its key growth driver sold with Elan PLC (ELN, ELN. ... Wall Street Journal European Stocks Post Weekly Decline; STMicroelectronics Drops - Oct 24, 2009 Elan Corp. sank 23 percent as its multiple sclerosis drug Tysabri was linked to 23 cases of a potentially fatal brain disease. Valeo SA advanced 4.9 percent ... Bloomberg Lilly, Gilead impress with Q3 sales growth - Oct 21, 2009 The company cut R&D and administrative costs by 12 percent, impressing analysts, who are expecting sales of the multiple sclerosis drug Tysabri to continue ... FiercePharma PDL BioPharma Announces Third Quarter 2009 Financial Results - Oct 28, 2009 The Company is changing its guidance due to less than anticipated product sales growth in Avastin, Herceptin and Tysabri. Also, anticipated royalties from ... Reuters Ifs, ands, and buts for Teva - Nov 3, 2009 Bank Hapoalim analyst Gilad Sarig said that some multiple sclerosis patients who take Tysabri may have switched to Copaxone. He also attributes the increase ... Globes Analyst upgrades, downgrades and initiations: CMCSA, CS, JWN, RCL, RIMM, YUM ... - Nov 2, 2009 The firm, which has a $50 target on the stock, believes Tysabri PML cases are reflected in shares. Deutsche Bank upgraded Nordstrom (NYSE: JWN) to Buy from ... BloggingStocks (blog) Double Take On Tysabri - Mar 9, 2006 We are issuing this alert because Elan jumped 24.5% in about 30 minutes of trading Wednesday to close at $15.81 when trading resumed on the New York Stock ... Forbes Biogen: How Deep a Wound Is Tysabri? - Mar 1, 2005 At a time when the medical community has grown especially jittery about drug safety, the news from biotech giant Biogen-Idec (BIIB ) couldn't have sounded ... BusinessWeek Why Biogen & Elan TYSABRI News Should Have Been Expected (BIIB, … - Aug 1, 2008 By 24/7 Wall St. This morning's share price reaction seen in Biogen-Idec Inc. (NASDAQ: BIIB) and Elan Corp. plc (NYSE: ELN) is severe. ... MarketWatch Comeback Begins for Tysabri - Jun 6, 2006 By Althea Chang. The official word has come down, and Tysabri is going back on the market, but US regulators determined that the label for the multiple ... TheStreet.com - TheStreet.com (subscription) Biogen Idec, Elan report second Tysabri death - MarketWatch - Mar 30, 2005 By Val Brickates Kennedy, MarketWatch. BOSTON (MarketWatch) -- Biogen Idec and Elan Pharmaceuticals reported late Wednesday that an ongoing investigation ... MarketWatch MS Drug Tysabri Approved for Crohn's Disease - Jan 15, 2008 By EJ Mundell. MONDAY, Jan. 14 (HealthDay News) -- Tysabri, a controversial drug used to treat multiple sclerosis, may also be used for patients with a ... Washington Post Special report: Market lays bet on Tysabri verdict - Mar 5, 2006 LAS VEGAS may be the home of gambling in America, but action at the Holiday Inn in Gaithersburg, Maryland, this week is attracting the attention of some ... Times Online Elan claims multiple Tysabri options - Oct 15, 2007 Elan Corporation Plc. said today it has several options for its share in the multiple sclerosis drug Tysabri if partner Biogen Idec Inc. is bought. ... Boston Globe The Virus That Took Down Tysabri - Mar 2, 2005 NEW YORK - The multiple sclerosis drug Tysabri might have squashed competition from some of the world's biotech giants, but in the end it was pushed off the ... Forbes FDA Questions Tysabri for Crohn's Disease - Jul 27, 2007 By Robert Steyer 07/27/07 - 02:06 PM EDT. Biogen Idec (BIIB Quote) and Elan (ELN Quote) skidded Friday after a Food and Drug Administration report ... TheStreet.com - TheStreet.com (subscription) Tysabri Is No Blockbuster - Aug 9, 2005 Shares of Biogen Idec and Elan soared on Tuesday as the companies said they had completed part of a safety review of their multiple sclerosis drug ... Forbes Biogen 3rd-qtr profit rises; Tysabri sales slow - Oct 21, 2008 By Toni Clarke. BOSTON, Oct 21 (Reuters) - Biogen Idec Inc (BIIB.O) reported third-quarter earnings on Tuesday that topped expectations, but sales of its ... Reuters European regulators reject Tysabri for Crohn's - Jul 19, 2007 LONDON/BOSTON, July 19 (Reuters) - European drug regulators have recommended against the use of Tysabri, a multiple sclerosis drug made by Biogen Idec Inc. ... Reuters Biogen, Elan's Tysabri Is Worth Rare, Fatal Risk, Patients Say - Mar 2, 2006 By Angela Zimm. March 2 (Bloomberg) -- Michael Barron, a 48-year-old former operator of a nuclear power plant, was so crippled by relapses in his multiple ... Bloomberg Board puts pressure on Elan chief over handling of Tysabri - Apr 3, 2005 KELLY MARTIN, Elan's chief executive, is set to come under intense pressure from members of his board and key institutional investors over his handling of ... Times Online Biogen profit up 11 pct, Tysabri shines - Jul 22, 2008 By Bill Berkrot. NEW YORK (Reuters) - Biogen Idec Inc (BIIB.O) reported a higher-than-expected second-quarter profit on Tuesday as sales of its closely ... Reuters UK FDA panel backs Tysabri for Crohn's - Aug 1, 2007 The Food and Drug Administration advisory panel meeting yesterday on Tysabri. (Stephanie Kuykendal/Bloomberg News). By Jeffrey Krasner, Globe Staff | August ... Boston Globe FDA Allows Tysabri Studies To Restart - Feb 15, 2006 The Food and Drug Administration will allow Elan (nyse: ELN - news - people ) and Biogen-Idec (nasdaq: BIIB - news - people )to begin a safety study of ... Forbes Tysabri Data Lift Biogen Idec, Elan - Apr 13, 2005 By Althea Chang. Biogen Idec (BIIB - commentary - Cramer's Take) and Elan (ELN - commentary - Cramer's Take) rose Wednesday after the companies late Tuesday ... TheStreet.com - TheStreet.com (subscription) Tysabri May Cause Liver Damage, Health Officials Say - Feb 27, 2008 By Steven Reinberg. WEDNESDAY, Feb. 27 (HealthDay News) -- The controversial multiple sclerosis drug Tysabri can start causing liver damage within six days ... Washington Post Tysabri Approval Still Likely Despite FDA Delay - Mar 22, 2006 Bear Stearns maintained an "underperform" rating on Biogen Idec after federal health regulators delayed a decision on whether to allow Tysabri back on the ... Forbes UK drugs body backs Tysabri for severe form of MS - Jul 3, 2007 LONDON, July 3 (Reuters) - Britain's cost-effectiveness watchdog has recommended that the multiple sclerosis drug Tysabri, made by Ireland's Elan Corp. ... Reuters UK Tysabri shows promise in Crohn's trial.(Biogen Idec Inc. of Cambridge... - Jul 1, 2005 Jul. 1--Biogen Idec Inc. of Cambridge and Elan Corp. of Ireland yesterday said a late-stage trial of their drug Tysabri showed that it was safe and ... Free with registration - Boston Globe - AccessMyLibrary.com MS drug Tysabri may promote brain infection: study - Dec 16, 2008 WASHINGTON (Reuters) - The popular multiple sclerosis drug Tysabri appears to promote a rare brain infection by suppressing immune system cells in the brain ... Reuters UK Mullen's Biogen Gets FDA OK On Tysabri; Investors Wary - Jun 5, 2006 New York - If James C. Mullen was pleased by a US Food and Drug Administration decision on Monday, patients suffering the misery of multiple sclerosis (MS) ... Forbes … Safety Issues Noted; The FDA found that Tysabri appeared more... - Mar 9, 2005 FDA reviewers found that Tysabri had an acceptable safety profile, ... Infections, including urinary and respiratory, were seen with Tysabri, but they were ... Pay-Per-View - Los Angeles Times - ProQuest Archiver Makers say 14,000 patients using MS drug Tysabri - Jul 23, 2007 DUBLIN, July 23 (Reuters) - Ireland's Elan Corp (ELN.I) and US partner Biogen Idec (BIIB.O) said on Monday around 14000 patients currently used their ... Reuters Texas man who obtained Tysabri dies of cancer - Oct 31, 2008 A prominent Democratic fundraiser, who recently made headlines by obtaining Biogen Idec Inc.'s drug Tysabri in defiance of the company's wishes, ... Boston Globe Elan higher after Tysabri quality news - Apr 7, 2006 Shares in Elan rose sharply today after it said the latest trials of its multiple sclerosis drug Tysabri on people who have the disease showed significant ... RTE.ie California; Firms' Shares Drop on Tysabri Illness Report - Jun 3, 2005 Shares of Elan Corp. and Biogen Idec Inc. tumbled after a fourth possible case of a rare and often fatal nerve disorder was reported in a patient taking the ... Pay-Per-View - Los Angeles Times - ProQuest Archiver UK drugs body again backs Tysabri for severe MS - Aug 22, 2007 LONDON, Aug 22 (Reuters) - Britain's cost-effectiveness watchdog has again recommended multiple sclerosis drug Tysabri, made by Ireland's Elan Corp (ELN. ... Reuters Tysabri Study Results Published - Mar 1, 2006 By Althea Chang. Biogen Idec (BIIB:Nasdaq) and its partner Elan (ELN:NYSE ADR) said data from two late-stage clinical trials of the multiple sclerosis drug ... TheStreet.com - TheStreet.com (subscription) Biogen, Elan Report Brain Infection in Tysabri Users - Jul 31, 2008 By Tom Randall. July 31 (Bloomberg) -- Biogen Idec Inc. and Elan Corp. reported two confirmed cases of a deadly brain infection in patients taking the ... Bloomberg The Tricky Biology Behind Tysabri - Mar 14, 2005 The story of Biogen Idec's (BIIB ) drug Tysabri, the multiple sclerosis treatment that was just withdrawn from the market, is a cautionary tale in the ... BusinessWeek Biogen Idec: No new brain infections with Tysabri - May 3, 2007 Biogen Idec said Thursday that there have been no new cases reported of a potentially fatal brain infection associated with its drug Tysabri since the ... Bizjournals.com Elan shares slip as US regulators delay expected return of Tysabri. - Mar 23, 2006 Shares in Irish biotech group Elan slipped yesterday as US drug regulators delayed the expected return of its breakthrough multiple sclerosis drug Tysabri ... Pay-Per-View - Irish Times - Factiva, from Dow Jones Tysabri causes third death - Dec 19, 2008 A multiple sclerosis patient died from a severe brain infection after taking Tysabri, the fourth such infection reported in five months since the drug was ... Bizjournals.com Tysabri: PML cases studied in medical journal - Jun 10, 2005 Elan's suspended multiple sclerosis drug Tysabri likely led to the brain infection that killed two patients, though whether the drug can still provide a ... RTE.ie New TYSABRI(R) Data to Be Presented at the European Committee for … - Oct 11, 2007 Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) announced that TYSABRI® (natalizumab) treatment significantly increases the proportion of ... RedOrbit 21,000 patients worldwide using Tysabri - Elan - Jan 7, 2008 Pharmaceutical company Elan has given an update on the use of its multiple sclerosis drug Tysabri, which it co-develops with Biogen Idec. ... RTE.ie … News - Nieuwe onderzoeksgegevens TYSABRI wijzen reductie gebruik … - Jun 10, 2006 Data Demonstrate TYSABRI Reduced Corticosteroid Use, Hospitalizations and ... The study also showed that TYSABRI therapy resulted in a 65% relative ... Netherlands Corporate News - Netherlands Corporate News (persbericht) Biogen's Potential Tysabri Boost Seen Fleeting - Sep 27, 2005 Credit Suisse First Boston maintained a "neutral" rating on Biogen Idec (nasdaq: BIIB - news - people ) after the biotechnology company announced late ... Forbes Biogen to test Tysabri as a cancer treatment - Sep 5, 2008 Biogen Idec has begun testing the multiple sclerosis drug Tysabri as a treatment for blood cancer. Cambridge, Mass.-based Biogen (Nasdaq: BIIB) and ... Bizjournals.com No new brain infection cases with MS drug Tysabri - Aug 28, 2007 BOSTON, Aug 28 (Reuters) - Biogen Idec Inc. (BIIB.O) said on Tuesday that as of mid-July there have been no new reported cases of a potentially deadly brain ... Reuters Tysabri Effective in Crohn's Trial - Oct 24, 2006 By TSC Staff 10/24/06 - 11:55 AM EDT. Drugmakers Biogen Idec(BIIB Quote) and Elan(ELN Quote) reported trial data showing that Tysabri helped maintain ... TheStreet.com - TheStreet.com (subscription) Elan Surges on Tysabri Hopes - Apr 28, 2005 By Robert Steyer. Elan (ELN:NYSE) on Thursday reported first-quarter results in which the loss was greater and the revenue was smaller than in the same ... TheStreet.com - TheStreet.com (subscription) Biogen Says Brain Illness Found in Tysabri Patient - Oct 29, 2008 By Elizabeth Lopatto. Oct. 29 (Bloomberg) -- Biogen Idec Inc. said a patient taking its multiple sclerosis drug Tysabri was diagnosed with a ... Bloomberg No new reports of ills since return of Tysabri - May 4, 2007 By Christopher Rowland, Globe Staff | May 4, 2007. Ten months and 10000 patients after the multiple sclerosis drug Tysabri returned to the market, ... Boston Globe Companies Educate People About Tysabri - May 10, 2006 By BRANDIE M. JEFFERSON. AP. BOSTON -- It was barely two hours after a panel recommended to the Food and Drug Administration that it allow the drug Tysabri ... Washington Post One drug, two views.(multiple sclerosis drug, Tysabri) - Jun 14, 2005 The chief executives of Biogen Idec Inc. and Elan Corp. have each made numerous comments about the fate of Tysabri, the multiple sclerosis drug the two ... Free with registration - Boston Globe - AccessMyLibrary.com Biogen Idec profit up 23% as Avonex and Rituxan sales grow - … - Apr 23, 2008 Biogen's newest MS drug, Tysabri, took in sales of $160 million. ... Biogen co-markets Tysabri with Elan Corp. , and Biogen said its take from Tysabri sales ... MarketWatch Elan Q1 loss doubled but Tysabri keeps on track - Apr 24, 2007 DUBLIN, April 24 (Reuters) - Drug-maker Elan Corp (ELN.I) posted a wider than expected first-quarter loss on Tuesday after repaying debt but said it was on ... Reuters New Data on TYSABRI(R) Presented at ECTRIMS Congress Demonstrate … - Sep 28, 2006 ZUG, Switzerland & DUBLIN, Ireland -- Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) announced today that data from the Phase III AFFIRM ... Free with registration - Business Wire - AccessMyLibrary.com Biogen, Elan Near Tysabri Filing - Sep 20, 2005 By Robert Steyer. Shares in Biogen Idec (BIIB:Nasdaq) and Elan (ELN:NYSE ADR) rose modestly after the drug companies updated investors on the regulatory ... TheStreet.com - TheStreet.com (subscription) Biogen, Elan See Rise in Tysabri Use - Apr 15, 2008 Biogen Idec (BIIB Quote) and Elan (ELN Quote) presented positive safety data and new patient rates for multiple sclerosis drug Tysabri, at the annual ... TheStreet.com - TheStreet.com (subscription) Elan sees 20,000 MS sufferers on Tysabri by end 07 - Jul 26, 2007 DUBLIN, July 26 (Reuters) - Irish drugmaker Elan Corp (ELN.I) said on Thursday it expected the number of multiple sclerosis (MS) sufferers being treated ... Reuters IN BRIEF / PHARMACEUTICALS; Tysabri Makers Find No New Brain … - Oct 18, 2005 The two pharmaceutical companies that make the drug Tysabri said they had found no new cases of a rare brain disease among nearly 1500 people who took the ... Pay-Per-View - Los Angeles Times - ProQuest Archiver Comeback Begins for Tysabri - Mar 29, 2006 The FDA's clearance was partly based on a risk-management plan designed to inform doctors and patients of the benefits and risks of Tysabri. ... TheStreet.com - TheStreet.com (subscription) Another Setback for Tysabri - May 26, 2005 ..."This new report is consistent with our long-held thesis that the discovery of additional PML cases is highly likely, and there is a low probability of ... TheStreet.com - TheStreet.com (subscription) Tysabri's Loss Hits Biogen | Robert Steyer News | Print Financial & … - Apr 27, 2005 Adelman and other executives said they are hopeful Tysabri will return to the ... The third patient was involved in a clinical trial to see if Tysabri could ... TheStreet.com - TheStreet.com (subscription) Another Setback for Tysabri - Jun 2, 2005 By Robert Steyer. Shares of Biogen Idec (BIIB - commentary - Cramer's Take) and Elan (ELN - commentary - Cramer's Take) fell Thursday after a newspaper said ... TheStreet.com - TheStreet.com (subscription) Two-Year Sentinel Data Evaluating TYSABRI ® in Addition to AVONEX ® … - Jul 18, 2005 Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) announced today that SENTINEL, the Phase III TYSABRI ® (natalizumab) add-on trial with ... ccnmatthews.com MS drug Tysabri closer to EU launch - Apr 28, 2006 CAMBRIDGE, Mass., April 28 (UPI) -- Biogen Idec and Elan said their multiple-sclerosis drug Tysabri has been recommended for approval in Europe. ... United Press International Elan, Biogen expect decision on Tysabri at end of March - Jan 23, 2006 LONDON (AFX) - Elan Corp and development partner Biogen Idec said they expect US regulators to decide by the end of March whether to allow their multiple ... Forbes Elan 'optimistic' on Tysabri return, earmarks cash for relaunch UPDATE - Jan 31, 2006 LONDON (AFX) - Ireland's biggest drugmaker Elan Corporation PLC has earmarked 150-170 mln usd to spend on the development and marketing of its multiple ... Forbes Elan Still Faces Considerable Uncertainty On Tysabri - Jul 29, 2005 Morgan Stanley reiterated an "underweight" rating on Elan (nyse: ELN - news - people ), saying considerable uncertainty still exists around the future of ... Forbes Biogen Idec Profit Rises 85% on Tysabri Sales Gains - Feb 6, 2008 By Luke Timmerman. Feb. 6 (Bloomberg) -- Biogen Idec Inc., the world's largest maker of multiple sclerosis drugs, said fourth-quarter profit rose 85 percent ... Bloomberg … Tied to Experimental MS Drug Stirs Debate; As Tysabri's makers... - Feb 18, 2006 But all aspects of the Tysabri clinical trials were approved by the FDA and by ... Researchers in one study noted that Tysabri nearly doubled patients' ... Pay-Per-View - Los Angeles Times - ProQuest Archiver Tysabri An Overhang On Biogen Idec's Q1 - Apr 25, 2006 Wachovia Securities reiterated a "market perform" rating on Biogen Idec ahead of the biotech firm's first-quarter earnings report. ... Forbes CORRECTION Elan, Biogen's MS drug Tysabri gets EU marketing go- … - Jun 29, 2006 LONDON (AFX) - Elan Corp and Biogen Idec's Tysabri has received European marketing approval as a treatment for relapsing remitting multiple sclerosis, ... Forbes Biogen Idec's Tysabri May Return To Market In 2006 - Oct 31, 2005 JP Morgan Securities upgraded shares of Biogen Idec (nasdaq: BIIB - news - people ) to "overweight" from "neutral" and said the odds are high the company's ... Forbes Biogen Idec, Elan Could See Strong Tysabri Launch - May 3, 2006 Bear Stearns maintained an "underperform" rating on Biogen Idec after the biotech firm announced Wednesday morning it will acquire privately-held Conforma ... Forbes Lower sales of Tysabri predicted - Aug 6, 2008 Financial analysts are predicting the number of patients using Tysabri will fall far below Biogen Idec Inc.'s forecast, following the Cambridge biotech ... Boston Globe Elan narrows 1Q loss on surging sales of MS drug Tysabri - Apr 24, 2008 AP Writer / April 24, 2008. DUBLIN, Ireland—Biotechnology company Elan Corp. PLC reported stronger first-quarter revenue and a narrower loss Thursday due to ... Boston Globe Elan spends $17m in hope of Tysabri comeback - Oct 28, 2005 By Richard Irving. ELAN, the disaster-prone drug maker that was once the Irish Republic's biggest company, disclosed yesterday that it has spent nearly $17 ... Times Online Elan shares fall as Tysabri patient diagnosed with PML - Oct 30, 2008 Shares in Irish pharmaceutical company Elan have fallen sharply today after another patient taking its multiple sclerosis drug Tysabri was diagnosed with a ... Irish Times EU watchdog assessing Tysabri brain disease cases - Aug 13, 2008 LONDON, Aug 13 (Reuters) - The European Medicines Agency said on Wednesday it was assessing two cases of a potentially deadly brain disease reported last ... Reuters India Biogen, Elan present positive phase 3 Tysabri data for MS sufferers - Oct 6, 2006 LONDON (AFX) - Biogen Idec and Elan Corp said conference data presented today shows Tysabri, the companies' multiple sclerosis drug, significantly reduces ... Forbes Biogen confident on Tysabri. - Oct 20, 2005 Oct. 20--Biogen Idec Inc.'s chief executive, James C. Mullen, said he expects the Food and Drug Administration to rule by June 30, 2006, on the company's ... Free with registration - Boston Globe - AccessMyLibrary.com Elan loss widens, sees 2008 revenue up 30% - Feb 13, 2008 Tysabri generated fourth-quarter sales of $129.1 million, ... Dublin-based Elan shares the rights for Tysabri with Biogen Idec Inc. (NASDAQ:BIIB) of the US ... MarketWatch Tysabri Gets Priority Review - Nov 17, 2005 By TSC Staff. Biogen Idec (BIIB:Nasdaq) and Elan (ELN:NYSE ADR) said the Food and Drug Administration accepted their supplemental biologics license ... TheStreet.com - TheStreet.com (subscription) EU follows US with Tysabri liver warning - Mar 20, 2008 LONDON, March 20 (Reuters) - The European Medicines Agency said on Thursday that warnings about liver injury should be added to the product information for ... Reuters Tysabri relaunch mooted for next year - Jul 7, 2005 In a report prepared by NCB Stockbrokers, senior analyst Dr Orla Hartford has reviewed the data available in Elan drug Tysabri's Biological License ... Ireland Online Biogen CEO says expects more Tysabri PML cases - Mar 18, 2008 By Toni Clarke. BOSTON, March 18 (Reuters) - The chief executive of Biogen Idec Inc (BIIB.O) said on Tuesday he expects to see more cases of a potentially ... Reuters Elan Says Remains Committed to Tysabri, Biogen Partnership - Dec 13, 2007 By Angela Cullen. Dec. 13 (Bloomberg) -- Elan Corp., the Irish drugmaker that developed the Tysabri multiple sclerosis drug with Biogen Idec Inc., ... Bloomberg A drug -- and hopes -- on hold.(multiple sclerosis, Tysabri) - Jun 24, 2005 Jun. 24--Dr. Amy Littell, a 38-year-old school psychologist with multiple sclerosis, was at work Feb. 28 when her 11-year-old daughter, Chloe, ... Free with registration - Boston Globe - AccessMyLibrary.com FDA approves resumed marketing of Tysabri.(Industry News) - Jul 1, 2006 The FDA recently approved an application for resumed marketing of Tysabri (natalizumab) subject to a special restricted distribution program. ... Free with registration - Pharmaceutical Processing - AccessMyLibrary.com Biogen and FDA Issue Drug Warning - Mar 17, 2005 Still, with Tysabri off the market at least temporarily, ... Biogen and Elan, its partner on Tysabri, suspended sales of that drug on Feb. ... New York Times Ireland: Fresh doubts over future of Elan's MS drug - Mar 6, 2005 Both patients were taking Tysabri with Avonex, an established MS drug developed by Biogen ... Atwood said this would make little difference for Tysabri. ... Times Online One Tysabri PML patient deteriorates, one improves - Sep 19, 2008 BOSTON (Reuters) - One of two patients who developed a potentially deadly brain infection after taking the multiple sclerosis drug Tysabri is deteriorating, ... Reuters MS Guessing Game Heats Up - Mar 9, 2006 Tysabri isn't back on the market yet, but the odds have dramatically increased ... A panel of medical experts on Wednesday said Tysabri, developed by Elan ... TheStreet.com - TheStreet.com (subscription) Biogen, Elan Again Put Fate Of Tysabri Into FDA's Hands - Sep 28, 2005 By Aaron Lorenzo. The FDA now finds itself in an unenviable position, after receiving an application to clear Tysabri (natalizumab) again, seven months ... BioWorld Online - BioWorld Online ON STATE STREET; Elan would toast Tysabri's recovery - Mar 22, 2005 That's why Tysabri, the newer drug, was pulled from the market pending further ... Biogen, which holds patents on both Avonex and Tysabri, was keen to sell ... Pay-Per-View - Boston Herald - ProQuest Archiver … News - Volgens nieuwe analyse geeft TYSABRI duurzame verbetering... - Sep 20, 2008 This post-hoc analysis provides the first evidence that TYSABRI is associated ... "These results show that TYSABRI treated patients are significantly more ... Netherlands Corporate News - Netherlands Corporate News (persbericht) … shares jump as US regulators raise review status on suspended... - Nov 18, 2005 Elan is developing Tysabri in conjunction with Cambridge, ... In November 2004, the FDA had approved Tysabri for sale to the approximately 350000 Americans ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com Report: Elan mulls Tysabri buy out from Biogen - Oct 16, 2007 Elan Corp. plc is weighing a possible buyout of Tysabri from development partner Biogen Idec if the company is sold. The Irish company (NYSE: ELN) owns a 50 ... Bizjournals.com FDA panels to review Biogen Idec's Tysabri - May 29, 2007 CAMBRIDGE, Mass., May 29 (UPI) -- Biogen Idec said Tuesday two US Food and Drug Administration advisory panels will review Tysabri for treatment of Crohn's ... United Press International A resurgent Tysabri is propelling growth, says Paul Clancy. (Essdras... - May 20, 2008 Three years ago, Biogen Idec Inc. reported some stunningly bad news. It was yanking Tysabri, its promising multiple sclerosis drug, off the market after it ... Boston Globe Risky MS drug would aim at Crohn's - Dec 16, 2006 Tysabri, a multiple sclerosis treatment that was only recently allowed back on the ... The wholsesale cost of a year's supply of Tysabri is about $29000. ... News & Observer Doctors Seen as Key to Tysabri Success; Makers of the pulled MS drug,... - May 16, 2006 Three thousand people took Tysabri in clinical trials. Once it was approved, an additional 7000 patients began therapy and 15000 awaited insurance ... Pay-Per-View - Los Angeles Times - ProQuest Archiver Brand Names/Synonyms: Tysabri is also known by the following brand names and/or synonymsTysabri; anti-VLA4; anti-alpha4 integrin ; Tysabri (Antegren) Drug Category: Tysabri is categorized under the following by the FDA: Immunomodulatory Agents Dosage Forms: Not Available Absorption: Not Available Interactions: Not Available Chemical IUPAC Name: Humanized anti a4 integrin antibody |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |